The Clinical Significance of Isocitrate Dehydrogenase 2 in Esophageal Squamous Cell Carcinoma

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2017 Apr 13

PMID 28401022

Citations 11

Authors

Xuan Chen

Wenzhe Xu

Cong Wang

Fang Liu

Shanghui Guan

Yi Sun

Xintong Wang

Dianzheng An

Zhihua Wen

Pengxiang Chen

Yufeng Cheng

Affiliations

Soon will be listed here.

Abstract

Isocitrate dehydrogenase 2 (IDH2) is the rate-limiting enzyme in the tricarboxylic acid (TCA) cycle in cellular metabolism. Growing evidence indicates that IDH2 plays a crucial role in the development of cancer. We aimed to investigate the expression level of IDH2 and its prognostic value in esophageal squamous cell cancer (ESCC). We evaluate the IDH2 expression and prognostic value in ESCC by immunohistochemical (IHC) staining, quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting. The cell counting kit-8 (CCK8), clonogenic and invasion assays were performed to verify the IDH2 function in vitro. The protein expression level of IDH2 was significantly upregulated in ESCC tissues (IHC, Western blotting, all <0.001) despite no significant difference at mRNA expression level (>0.05). Kaplan-Meier analysis showed that IDH2 overexpression in ESCC patients was significantly related to worse overall survival (OS) and progression-free survival (PFS), = 0.003 and 0.002, respectively. The univariate and multivariate analyses revealed that IDH2 overexpression served as an independent prognostic factor for OS and PFS (all <0.005) in ESCC. The OD value, colony formation and invasive cell number were decreased in the shIDH2 groups (all <0.0001). The upregulation of IDH2 in ESCC cells showed opposite effects (all <0.05). Additionally, IDH2 knockdown phenotype can be rescued by shRNA-resistant IDH2 (all <0.05). These results demonstrated that IDH2 was upregulated in ESCC and could be used as a valuable prognostic marker for ESCC patients.

Citing Articles

Exploring metabolic reprogramming in esophageal cancer: the role of key enzymes in glucose, amino acid, and nucleotide pathways and targeted therapies.

Dong X, Chen L, Xu Y, Wu P, Xie T, Liu Z Cancer Gene Ther. 2025; 32(2):165-183.

PMID: 39794467 DOI: 10.1038/s41417-024-00858-5.

Wild-type IDH2 is a therapeutic target for triple-negative breast cancer.

Li J, Yu T, Zeng P, Tian J, Liu P, Qiao S Nat Commun. 2024; 15(1):3445.

PMID: 38658533 PMC: 11043430. DOI: 10.1038/s41467-024-47536-6.

The relative isoform expression levels of isocitrate dehydrogenase in breast cancer: IDH2 is a potential target in MDA-MB-231 cells.

Piao S, Kim S, Seo Y, Lee J, Jeon S, Vu G Korean J Clin Oncol. 2024; 19(2):60-68.

PMID: 38229490 PMC: 10792364. DOI: 10.14216/kjco.23011.

Targeting Mitochondrial IDH2 Enhances Antitumor Activity of Cisplatin in Lung Cancer via ROS-Mediated Mechanism.

Li H, Li J, Lu W, Yang J, Xia Y, Huang P Biomedicines. 2023; 11(2).

PMID: 36831011 PMC: 9953680. DOI: 10.3390/biomedicines11020475.

Metabolic implications of non-electrogenic ATP/ADP exchange in cancer cells: A mechanistic basis for the Warburg effect.

Lemasters J Biochim Biophys Acta Bioenerg. 2021; 1862(7):148410.

PMID: 33722515 PMC: 8096716. DOI: 10.1016/j.bbabio.2021.148410.

References

Li L, Yu X, Yang Y, Zhang C, Guo L, Lu S . Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo. Int J Cancer. 2009; 125(7):1505-13. DOI: 10.1002/ijc.24513. View

Leonardi R, Subramanian C, Jackowski S, Rock C . Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. J Biol Chem. 2012; 287(18):14615-20. PMC: 3340216. DOI: 10.1074/jbc.C112.353946. View

Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S . Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011; 19(1):17-30. PMC: 3229304. DOI: 10.1016/j.ccr.2010.12.014. View

Paschka P, Schlenk R, Gaidzik V, Habdank M, Kronke J, Bullinger L . IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010; 28(22):3636-43. DOI: 10.1200/JCO.2010.28.3762. View

Mandard A, Hainaut P, Hollstein M . Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res. 2000; 462(2-3):335-42. DOI: 10.1016/s1383-5742(00)00019-3. View

de Sousa Abreu R, Penalva L, Marcotte E, Vogel C . Global signatures of protein and mRNA expression levels. Mol Biosyst. 2009; 5(12):1512-26. PMC: 4089977. DOI: 10.1039/b908315d. View

Liu Y, Gilbert M, Kyprianou N, Rangnekar V, Horbinski C . The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells. Acta Neuropathol. 2014; 128(5):723-32. PMC: 4201966. DOI: 10.1007/s00401-014-1334-7. View

Benhar M, Shytaj I, Stamler J, Savarino A . Dual targeting of the thioredoxin and glutathione systems in cancer and HIV. J Clin Invest. 2016; 126(5):1630-9. PMC: 4855928. DOI: 10.1172/JCI85339. View

Ward P, Patel J, Wise D, Abdel-Wahab O, Bennett B, Coller H . The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17(3):225-34. PMC: 2849316. DOI: 10.1016/j.ccr.2010.01.020. View

10.

Altenberg B, Greulich K . Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics. 2004; 84(6):1014-20. DOI: 10.1016/j.ygeno.2004.08.010. View

11.

Jo S, Son M, Koh H, Lee S, Song I, Kim Y . Control of mitochondrial redox balance and cellular defense against oxidative damage by mitochondrial NADP+-dependent isocitrate dehydrogenase. J Biol Chem. 2001; 276(19):16168-76. DOI: 10.1074/jbc.M010120200. View

12.

Lv Q, Xing S, Li Z, Li J, Gong P, Xu X . Altered expression levels of IDH2 are involved in the development of colon cancer. Exp Ther Med. 2012; 4(5):801-806. PMC: 3493704. DOI: 10.3892/etm.2012.676. View

13.

Lu J, Holmgren A . Thioredoxin system in cell death progression. Antioxid Redox Signal. 2012; 17(12):1738-47. DOI: 10.1089/ars.2012.4650. View

14.

Dong W, Shen R, Cheng S . Reduction of TIP30 in esophageal squamous cell carcinoma cells involves promoter methylation and microRNA-10b. Biochem Biophys Res Commun. 2014; 453(4):772-7. DOI: 10.1016/j.bbrc.2014.10.016. View

15.

Wise D, Ward P, Shay J, Cross J, Gruber J, Sachdeva U . Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A. 2011; 108(49):19611-6. PMC: 3241793. DOI: 10.1073/pnas.1117773108. View

16.

Turcan S, Rohle D, Goenka A, Walsh L, Fang F, Yilmaz E . IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012; 483(7390):479-83. PMC: 3351699. DOI: 10.1038/nature10866. View

17.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

18.

Metzger R, Schneider P, Warnecke-Eberz U, Brabender J, Holscher A . Molecular biology of esophageal cancer. Onkologie. 2004; 27(2):200-6. DOI: 10.1159/000076913. View

19.

Jones P, Laird P . Cancer epigenetics comes of age. Nat Genet. 1999; 21(2):163-7. DOI: 10.1038/5947. View

20.

Figueroa M, Abdel-Wahab O, Lu C, Ward P, Patel J, Shih A . Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18(6):553-67. PMC: 4105845. DOI: 10.1016/j.ccr.2010.11.015. View